Skip to main content

Table 1 Clinical features of the WT TARGET cohort

From: Downregulated TICAM1 is a prognostic biomarker and associated with immune tolerance of Wilms tumor patients

 

TARGET(N = 126)

Gender

 Female

70(55.56%)

 Male

56(44.44%)

Age

  < 3 years

33(26.19%)

  > 3 years

93(73.80%)

Stage

 I-II

68(53.97%)

 III-IV

58(46.03%)

Evenet

 Relapse/progression

101(80.06%)

 None

25(19.84)

TICAM1

 High-expression`

51(40.48%)

 Low-expression

75(59.52%)